Stock Watch: Smiles And Survivorship In BMS’s Q2 Earnings

Portfolio Reclassifications Can Be Double-Edged

Grouping products into 'growth' or 'launches' is a statement of high expectations. Reporting sales in China has had similar growth connotations, until recently.      

Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from Business